Founded in 1999 and listed on the Australian Securities Exchange in 2004, Cogstate (ASX.CGS) is a world-class neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture.
Learn About Cogstate
Cogstate is advancing the development of new medicines by improving clinical outcome measures (6:09min)
Proprietary assessments designed for heightened sensitivity, delivered on a flexible technology platform (2:19min)
Broad Application for Our Full Range of Solutions (4:10min)
The Scientific Expertise to Earn Trusted-Partner Relationships (1:36min)
Cogstate’s future: the growing need for earlier and more efficient detection of cognitive decline in the community (4:28min)
- Cogstate’s easy-to-use, computerised cognitive testing is based on science which has been widely accepted and validated both academically and commercially through hundreds of peer-reviewed publications
- Cogstate solutions serve four distinct markets: Clinical Trials, Healthcare, Academic Research and Brain Injury
- Cogstate has a history of strong financial performance with the Clinical Trials business enabling the company to self-fund R&D and commercialisation opportunities
- Cogstate leverages its leading expertise in cognitive testing to penetrate growing markets in Healthcare and Brain Injury
Information for current and prospective Cogstate investors can be found in this section of our website.